A case of lung adenocarcinoma presenting with leptomeningeal carcinomatosis successfully treated with afati-nib after erlotinib-lnduced hepatotoxicity

Hiroaki Tanaka; Minehiko Inomata; Ryuji Hayashi; Kazuki Shimokawa; Kotaro Tokui; Seisuke Okazawa; Kenta Kambara; Toru Yamada; Toshiro Miwa; Tatsuhiko Kashii; Hirofumi Konishi; Kazuyuki Tobe

A case of lung adenocarcinoma presenting with leptomeningeal carcinomatosis successfully treated with afati-nib after erlotinib-lnduced hepatotoxicity

Hiroaki Tanaka, Minehiko Inomata, Ryuji Hayashi, Kazuki Shimokawa, Kotaro Tokui, Seisuke Okazawa, Kenta Kambara, Toru Yamada, Toshiro Miwa, Tatsuhiko Kashii, Hirofumi Konishi, Kazuyuki Tobe

Research output: Contribution to journal › Article › peer-review

Abstract

A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging (MRl). Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRl findings were obtained. However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena. We switched the treatment to afatinib monotherapy, and his consciousness improved immediately. Progression-free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9.4 months, respectively. This clinical course suggests activity of afatinib for central nervous system lesions of EGFR-mutated lung cancer.

Original language	English
Pages (from-to)	595-597
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	44
Issue number	7
State	Published - 2017/07

Keywords

Afatinib
Epidermal growth factor receptor
Leptomeningeal carcinomatosis

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0032529ded3c4088a750ee8574ef654d,

title = "A case of lung adenocarcinoma presenting with leptomeningeal carcinomatosis successfully treated with afati-nib after erlotinib-lnduced hepatotoxicity",

abstract = "A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging (MRl). Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRl findings were obtained. However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena. We switched the treatment to afatinib monotherapy, and his consciousness improved immediately. Progression-free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9.4 months, respectively. This clinical course suggests activity of afatinib for central nervous system lesions of EGFR-mutated lung cancer.",

keywords = "Afatinib, Epidermal growth factor receptor, Leptomeningeal carcinomatosis",

author = "Hiroaki Tanaka and Minehiko Inomata and Ryuji Hayashi and Kazuki Shimokawa and Kotaro Tokui and Seisuke Okazawa and Kenta Kambara and Toru Yamada and Toshiro Miwa and Tatsuhiko Kashii and Hirofumi Konishi and Kazuyuki Tobe",

year = "2017",

month = jul,

language = "英語",

volume = "44",

pages = "595--597",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "7",

}

TY - JOUR

T1 - A case of lung adenocarcinoma presenting with leptomeningeal carcinomatosis successfully treated with afati-nib after erlotinib-lnduced hepatotoxicity

AU - Tanaka, Hiroaki

AU - Inomata, Minehiko

AU - Hayashi, Ryuji

AU - Shimokawa, Kazuki

AU - Tokui, Kotaro

AU - Okazawa, Seisuke

AU - Kambara, Kenta

AU - Yamada, Toru

AU - Miwa, Toshiro

AU - Kashii, Tatsuhiko

AU - Konishi, Hirofumi

AU - Tobe, Kazuyuki

PY - 2017/7

Y1 - 2017/7

N2 - A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging (MRl). Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRl findings were obtained. However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena. We switched the treatment to afatinib monotherapy, and his consciousness improved immediately. Progression-free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9.4 months, respectively. This clinical course suggests activity of afatinib for central nervous system lesions of EGFR-mutated lung cancer.

AB - A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging (MRl). Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRl findings were obtained. However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena. We switched the treatment to afatinib monotherapy, and his consciousness improved immediately. Progression-free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9.4 months, respectively. This clinical course suggests activity of afatinib for central nervous system lesions of EGFR-mutated lung cancer.

KW - Afatinib

KW - Epidermal growth factor receptor

KW - Leptomeningeal carcinomatosis

UR - http://www.scopus.com/inward/record.url?scp=85029667655&partnerID=8YFLogxK

M3 - 学術論文

C2 - 28790264

AN - SCOPUS:85029667655

SN - 0385-0684

VL - 44

SP - 595

EP - 597

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 7

ER -

A case of lung adenocarcinoma presenting with leptomeningeal carcinomatosis successfully treated with afati-nib after erlotinib-lnduced hepatotoxicity

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Fingerprint

Cite this